Biochemical characterization of the muscarinic cholinergic receptor in human brain: alterations in Huntington's disease
Wastek, G.J.; Yamamura, H.I.
Molecular Pharmacology 14(5): 768-780
1978
ISSN/ISBN: 0026-895X PMID: 152407 Document Number: 127622
quinuclidinyl benzilate binding were determined in each of the 3 control brain regions and in Huntington's diseased putamen at different receptor concentrations. Each of these brain regions had a "true" Kd between 20 and 40 pM. These studies, plus inhibition studies using dexetimide, the biologically-active stereoisomer of benzetimide, revealed that the decreases in ligand binding were due to receptor loss than to changes in receptor affinity.